We also discovered that miR-155 overexpression intrinsically increased PD-L1 expression in both human primary breast cancer cells and murine breast cancer cell lines, which may explain our in vivo findings showing the miR-155–overexpressing tumors are sensitive to ICB therapy. This evidence concerns the gene CD274 and breast carcinoma.